Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): Emerging strategies for cancer therapy
Qi Hao,
No information about this author
Wenzhe Zhao,
No information about this author
Zhijia Li
No information about this author
et al.
European Journal of Medicinal Chemistry,
Journal Year:
2025,
Volume and Issue:
289, P. 117465 - 117465
Published: March 1, 2025
Language: Английский
Dynamics Insights into CDK4/6-CyclinD1 Complex Stability Modulated by Abemaciclib
Physical Chemistry Chemical Physics,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
The
CDK4/6–CyclinD1
complex,
a
fundamental
component
of
the
cell
cycle
regulatory
mechanism,
is
associated
with
numerous
cancers.
Language: Английский
Innovative Cancer Therapies: Targeting Oncogenic Pathways through Placental Immunology, PROTAC Technology, and Kinase Degradation
ACS Medicinal Chemistry Letters,
Journal Year:
2024,
Volume and Issue:
15(12), P. 2077 - 2079
Published: Nov. 11, 2024
Recent
advancements
in
cancer
therapy
have
led
to
groundbreaking
approaches
targeting
critical
oncogenic
pathways.
This
Patent
Highlight
explores
four
essential
patents
that
focus
on
modulating
ligand–receptor
interactions
from
placental
immunology,
degrading
RAF
proteins
with
MEK1/2
degraders,
and
employing
PROTAC
technology
degrade
Cyclin
D,
CDK4,
CDK6
proteins.
These
innovations
aim
overcome
traditional
limitations
address
resistance
cancers
such
as
breast,
lung,
RAS-altered
cancers.
publication
examines
these
inventions'
mechanisms,
findings,
implications
modern
treatment.
Language: Английский